jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Nov. 10, 2009

Dec. 17, 2018

jRCT1080220914

A prospective observational study of the efficacy and safety of CPT-11 based regimens (CPT-11+platinum analogues) for UGT1A1 genotype guided patients

A prospective observational study of the efficacy and safety of CPT-11 based regimens (CPT-11+platinum analogues) for UGT1A1 genotype guided patients

version:
date:

DAIICHI SANKYO COMPANY, LIMITED

+81-3-6225-1047

DAIICHI SANKYO COMPANY, LIMITED

+81-3-6225-1047

1000

Observational

Prospective, cohort

N/A

1. Small cell lung cancer, non-small cell lung cancer, cervical cancer, ovarian cancer and gastric cancer
2. Patients to receiving CPT-11 plus platinum anolaogues regimens
Age requirement none

1. Contraindications of CPT-11
2. ECOG PS 3-4

No limit
No limit

Both

Small cell lung cancer, non-small cell lung cancer, cervical cancer, ovarian cancer and gastric cancer (inoperable or recurrent)

investigational material(s)
Generic name etc : Irinotecan hydrochloride
INN of investigational material :
Therapeutic category code : 424 Antineoplastic preparations extracted from plants
Dosage and Administration for Investigational material : Approved doses and schedules

control material(s)
Generic name etc : None
INN of investigational material :
Therapeutic category code : --- Other
Dosage and Administration for Investigational material : None

Safety
None

Efficacy
None

DAIICHI SANKYO COMPANY, LIMITED
None
None
None
None

JapicCTI-090946

History of Changes

No Publication date
7 Dec. 17, 2018 (this page) Changes
6 April. 10, 2013 Detail Changes
5 April. 10, 2013 Detail Changes
4 Mar. 29, 2011 Detail Changes
3 Mar. 29, 2011 Detail Changes
2 Nov. 10, 2009 Detail Changes
1 Nov. 10, 2009 Detail